Entasis Therapeutics Holdings Inc. [NASDAQ: ETTX] price surged by 2.94 percent to reach at $0.06. The company report on October 14, 2020 that Entasis Therapeutics Highlights Multiple Data Presentations at Virtual ID Week.
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the company will have multiple data presentations at the virtual ID Week, being held October 21-25, 2020.
The details of the poster presentations include:.
A sum of 1960595 shares traded at recent session while its average daily volume was at 180.16K shares. Entasis Therapeutics Holdings Inc. shares reached a high of $2.207 and dropped to a low of $2.02 until finishing in the latest session at $2.10.
The average equity rating for ETTX stock is currently 1.80, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Entasis Therapeutics Holdings Inc. [ETTX]:
Cantor Fitzgerald have made an estimate for Entasis Therapeutics Holdings Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 09, 2020. While these analysts kept the previous recommendation, ROTH Capital raised their target price to Buy. The new note on the price target was released on July 13, 2020, representing the official price target for Entasis Therapeutics Holdings Inc. stock.
The Average True Range (ATR) for Entasis Therapeutics Holdings Inc. is set at 0.15, with the Price to Sales ratio for ETTX stock in the period of the last 12 months amounting to 8.27. The Price to Book ratio for the last quarter was 0.73, with the Price to Cash per share for the same quarter was set at 1.84.
ETTX Stock Performance Analysis:
Entasis Therapeutics Holdings Inc. [ETTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.94. With this latest performance, ETTX shares dropped by -29.29% in over the last four-week period, additionally sinking by -25.80% over the last 6 months – not to mention a drop of -63.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ETTX stock in for the last two-week period is set at 36.37, with the RSI for the last a single of trading hit 39.65, and the three-weeks RSI is set at 37.90 for Entasis Therapeutics Holdings Inc. [ETTX]. The present Moving Average for the last 50 days of trading for this stock 2.57, while it was recorded at 2.03 for the last single week of trading, and 3.28 for the last 200 days.
Insight into Entasis Therapeutics Holdings Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Entasis Therapeutics Holdings Inc. [ETTX] shares currently have an operating margin of -670.51. Entasis Therapeutics Holdings Inc.’s Net Margin is presently recorded at -626.43.
Return on Total Capital for ETTX is now -73.99, given the latest momentum, and Return on Invested Capital for the company is -69.40. Return on Equity for this stock declined to -70.14, with Return on Assets sitting at -62.51. When it comes to the capital structure of this company, Entasis Therapeutics Holdings Inc. [ETTX] has a Total Debt to Total Equity ratio set at 4.33. Additionally, ETTX Total Debt to Total Capital is recorded at 4.15, with Total Debt to Total Assets ending up at 3.58. Long-Term Debt to Equity for the company is recorded at 3.13, with the Long-Term Debt to Total Capital now at 3.00.
Reflecting on the efficiency of the workforce at the company, Entasis Therapeutics Holdings Inc. [ETTX] managed to generate an average of -$932,979 per employee. Receivables Turnover for the company is 4.77 with a Total Asset Turnover recorded at a value of 0.10.Entasis Therapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.90 and a Current Ratio set at 8.90.
ETTX Stock EPS
With the latest financial reports released by the company, Entasis Therapeutics Holdings Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.87/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 69.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ETTX.
Entasis Therapeutics Holdings Inc. [ETTX] Insider Position Details
There are presently around $16 million, or 40.70% of ETTX stock, in the hands of institutional investors. The top three institutional holders of ETTX stocks are: NOVO HOLDINGS A/S with ownership of 2,181,843, which is approximately 0% of the company’s market cap and around 68.40% of the total institutional ownership; BLACKSTONE GROUP INC, holding 1,350,490 shares of the stock with an approximate value of $2.84 million in ETTX stocks shares; and SOFINNOVA INVESTMENTS, INC., currently with $2.48 million in ETTX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Entasis Therapeutics Holdings Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 10 institutional holders increased their position in Entasis Therapeutics Holdings Inc. [NASDAQ:ETTX] by around 120,377 shares. Additionally, 8 investors decreased positions by around 1,019,509 shares, while 7 investors held positions by with 6,274,760 shares. The mentioned changes placed institutional holdings at 7,414,646 shares, according to the latest SEC report filing. ETTX stock had 5 new institutional investments in for a total of 15,854 shares, while 3 institutional investors sold positions of 919 shares during the same period.